<DOC>
	<DOCNO>NCT01499355</DOCNO>
	<brief_summary>The primary objective study assess efficacy BIIB023 add-on treatment background therapy compare placebo combination background therapy treatment participant active , biopsy-proven lupus nephritis . The secondary objective study assess safety tolerability BIIB023 compare placebo study population .</brief_summary>
	<brief_title>BIIB023 Proof-of-Concept Study Participants With Lupus Nephritis</brief_title>
	<detailed_description>Participants complete study Week 52 offer option enter Extension study separate protocol 211LE202 ( NCT0193089 ) .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Key Documented diagnosis systemic lupus erythematosus ( SLE ) accord current American College Rheumatology ( ACR ) criterion . At least 4 ACR criterion must document , 1 must positive antinuclear antibody ( ANA ) , anti Sm , anti dsDNA antibody . Diagnosis International Society Nephrology/Renal Pathology Society ( ISN/RPS ) 2003 Class III IV lupus nephritis either active active/chronic disease , confirm biopsy within 3 month prior Screening . Participants permit co exist Class V lupus nephritis . If renal biopsy perform within 3 month Screening Visit , one perform Screening Period eligibility criterion confirm . The local histological diagnosis must confirm central study pathologist . Must proteinuria Screening ( 24 hour urine sample collection ) define urinary protein : creatinine ratio ( uPCR ) &gt; 1.0 mg/mg . Key Retinitis , poorlycontrolled seizure disorder , acute confusional state , myelitis , stroke stroke syndrome , cerebellar ataxia , dementia currently active result SLE Screening Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min per 1.73 m^2 ( calculate use abbreviated Modification Diet Renal Disease equation ) presence oliguria endstage renal disease require dialysis transplantation Subjects require dialysis within 12 month prior Screening History renal transplant Treatment biologic Bcelldepleting therapy ( e.g. , antiCD20 [ rituximab ] , antiCD22 [ epratuzumab ] , antiBLyS/Bcell activate factor [ e.g. , briobacept , belimumab ] therapy ) , TACIIg within 12 month prior Runin Day 1 . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>